Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Factors associated with disease progression among hormone receptor-positive breast cancer patients treated with endocrine therapy: A 5-year cross-sectional, retrospective follow-up study

Nurul Sahida Rani, Mohd Shahezwan Abd Wahab, Hanis Hanum Zulkifly, Siti Hartinie Mohamad.




Abstract
Cited by 3 Articles

Endocrine therapy (ET) has shown clinical benefits for hormone receptor (HR)-positive breast cancer (BCa) patients. However, it is important to monitor patients’ response to ET. The present study aims to identify the factors associated with disease progression 1 year after ET initiation in a sample of HR-positive BCa patients at Hospital Sultanah Nur Zahirah, a Malaysian public hospital. Patients were identified from the Cancer Registry of the Terengganu State Health Department. Female patients aged ≥18 years, diagnosed with HR-positive BCa during the period from 2011 to 2014, and who were prescribed with at least one type of ET were included and retrospectively followed-up for 5 years. Disease progression that occurred after 1 year of ET was recorded. Adherence was measured using the medication possession ratio (MPR). Of all 103 BCa patients included in the study, 31.1% had disease progression after 1 year of ET initiation. Late-stage BCa, distant metastasis at diagnosis, MPR value of

Key words: Breast cancer, disease progression, hormone receptor-positive, endocrine therapy, Malaysia.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.